表紙
市場調查報告書

思覺失調症治療藥市場 - 成長,趨勢,及預測(2019年-2024年)

Schizophrenia Drugs Market - Growth, Trends, and Forecast (2019 - 2024)

出版商 Mordor Intelligence LLP 商品編碼 871430
出版日期 內容資訊 英文 114 Pages
商品交期: 2-3個工作天內
價格
Back to Top
思覺失調症治療藥市場 - 成長,趨勢,及預測(2019年-2024年) Schizophrenia Drugs Market - Growth, Trends, and Forecast (2019 - 2024)
出版日期: 2019年05月01日內容資訊: 英文 114 Pages
簡介

本報告提供全球思覺失調症治療藥市場的相關調查,市場概況和成長要素、阻礙因素,各治療等級、治療方法、地區的市場分析,競爭情形,主要企業的簡介等資訊彙整。

目錄

第1章 簡介

  • 研究成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 市場成長要素
    • 思覺失調症及相關疾病的盛行率上升
    • 對精神衛生的政府及醫療機關的焦點擴大
    • 對研究開發的投資擴大
  • 市場阻礙因素
    • 藥物相關中毒病例的增加
    • 主要醫藥品的專利失效
  • 波特五力分析
    • 新加入廠商的威脅
    • 買主/消費者談判力
    • 供應商談判力
    • 替代產品的威脅
    • 產業的競爭

第5章 市場區隔

  • 各治療等級
    • 第二代抗精神病藥
    • 第三代抗精神病藥
    • 其他
  • 各治療法
    • 口服
    • 注射劑
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東及非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Alkermes plc
    • Allergan plc
    • AstraZeneca
    • Bristol-Myers Squibb
    • Eli Lilly and Company
    • Johnson & Johnson
    • Pfizer, Inc
    • 大日本住友製藥株式會社
    • Vanda Pharmaceuticals

第7章 市場機會及今後趨勢

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 64928

Market Overview

Schizophrenia is a mental disorder characterized by disruptions in thought processes, perceptions, emotional responsiveness, and social interactions. Although the course of schizophrenia varies among individuals, schizophrenia is typically persistent and can be both severe and disabling. Schizophrenia is typically diagnosed in the late teen years, in the early thirties and tends to emerge earlier in males (late adolescence - early twenties) than females (early twenties - early thirties). More subtle changes in cognition and social relationships may precede the actual diagnosis, often by years. Findings from the 2016 global burden of the disease study indicated that population growth and aging has led to an increasing disease burden attributable to schizophrenia, globally, especially in the middle-income countries. Globally, an estimated 21 million people are living with schizophrenia and this number is likely to continue to rise with population aging and growth. Canada also has a high prevalence of schizophrenia attributable to three possible factors. Firstly, many studies have found that immigrants have an increased incidence of schizophrenia in both the first and second generations. Canada has a high rate of immigration, about twice that of the United States; 20% of Canadians were born in another country. Secondly, schizophrenia is more common in countries at high latitude, although the cause of this effect is unknown. Thirdly, urban populations have a greater prevalence of schizophrenia, and 80% of Canadians live in cities.

Hence, the rise in the incidence of the disease and the increasing need to manage them effectively has led to the growth of the Schizophrenia Drugs market.

Scope of the Report

Schizophrenia is characterized by delusions, hallucinations, and other cognitive difficulties, which can often be a lifelong struggle. Schizophrenia is a chronic and severe mental disorder that affects how a person thinks, feels, and behaves. People with schizophrenia may seem like they have lost touch with reality. Although schizophrenia is not as common as other mental disorders, the symptoms can be very disabling.

Key Market Trends

Second-generation Antipsychotics is Expected to Grow with a high CAGR in the Forecasted Period

Schizophrenia is a serious mental illness, which for some people can become a long term problem. The usual first-line treatment for schizophrenia is antipsychotic medication. One of the commonly preferred medications is risperidone that works in the brain to treat schizophrenia. It is also known as a second generation antipsychotic (SGA) or atypical antipsychotic. Risperidone rebalances dopamine and serotonin to improve thinking, mood, and behavior. Risperidone may help some or all of these symptoms of schizophrenia and is also FDA approved for acute treatment of manic or mixed episodes of bipolar disorder, maintenance (long-term) treatment of the bipolar disorder (Risperdal Consta® only), and irritability associated with autistic disorders. In cases where patients do not respond well to these medications, high doses are often used. This can cause severe adverse effects and set up a cycle where individuals gain some benefit from the medication, develop side effects, then stop taking it and relapse. Therefore, it would be helpful to find the optimum dose of each antipsychotic for different groups of people. There are several second-generation drugs available in the market which are commonly proposed by the doctors/physicians, and is thus well established in the market. Hence, due to the above-mentioned reasons, the market for second-generation antipsychotics is likely to grow steadily in the Schizophrenia Drugs market.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall market, throughout the forecast period. In the North America region, the United States holds the largest market share and this is due to the due to a large section of the population approaching such medications therapy in hectic lifestyle from several parts of the world. The country also offers highly advanced medical care, for early treatment capabilities, along with more government involvement in increasing healthcare expenditure which has helped the growth of the schizophrenia drugs market in the country.

Competitive Landscape

The Schizophrenia Drugs market is competitive and consists of major players and small players. In terms of market share, these major players currently dominate the market. Some of the major players of the market are Alkermes plc, Bristol-Myers Squibb, Eli Lilly and Company, Johnson & Johnson, Allergan plc and are among others.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rise in the Prevalence of Schizophrenia and Associated Disorders
    • 4.2.2 Increase in Focus of Governments and Health Care Organizations on Mental Health
    • 4.2.3 Growing Investments in Research and Development
  • 4.3 Market Restraints
    • 4.3.1 Increase in Cases of Addiction Associated with these Drugs
    • 4.3.2 Patent Expiry of Major Drugs
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Therapeutic Class
    • 5.1.1 Second-Generation Antipsychotics
    • 5.1.2 Third-Generation Antipsychotics
    • 5.1.3 Others
  • 5.2 By Treatment
    • 5.2.1 Oral
    • 5.2.2 Injectables
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 US
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 UK
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Alkermes plc
    • 6.1.2 Allergan plc
    • 6.1.3 AstraZeneca
    • 6.1.4 Bristol-Myers Squibb
    • 6.1.5 Eli Lilly and Company
    • 6.1.6 Johnson & Johnson
    • 6.1.7 Pfizer, Inc
    • 6.1.8 Sumitomo Dainippon Pharma
    • 6.1.9 Vanda Pharmaceuticals

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top